IGC Pharma (FRA:IGS1) Total Stockholders Equity : €5.98 Mil (As of Dec. 2024)

View and export this data going back to 2010. Start your Free Trial

What is IGC Pharma Total Stockholders Equity?

IGC Pharma's Total Stockholders Equity for the quarter that ended in Dec. 2024 was €5.98 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. IGC Pharma's Book Value per Share for the quarter that ended in Dec. 2024 was €0.08. The ratio of a company's debt over equity can be used to measure how leveraged this company is. IGC Pharma's Debt-to-Equity for the quarter that ended in Dec. 2024 was 0.04.

IGC Pharma Total Stockholders Equity Historical Data

The historical data trend for IGC Pharma's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IGC Pharma Total Stockholders Equity Chart

IGC Pharma Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Total Stockholders Equity

Get a 7-Day Free Trial

24.02

27.56

21.69

13.93

6.74

IGC Pharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Stockholders Equity	Get a 7-Day Free Trial															8.30	6.74	7.32	6.65	5.98

IGC Pharma (FRA:IGS1) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

IGC Pharma's Book Value per Share for the quarter that ended in Dec. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(5.977	-	0)	/	78.203
	=	0.08

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

IGC Pharma's Debt-to-Equity for the quarter that ended in Dec. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.118	+	0.139)	/	5.977
	=	0.04

IGC Pharma Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of IGC Pharma's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

IGC Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGC Pharma Inc (FRA:IGS1) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

IGC:USA

Address

10224 Falls Road, Potomac, MD, USA, 20854

Website

https://www.igcinc.us

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

IGC Pharma Headlines

No Headlines